Barinthus Biotherapeutics PLC

This management proposal asks shareholders to authorize the Audit Committee to determine the auditors’ remuneration for the coming fiscal year. Operationally, the Audit Committee—not the full Board—would set the fee terms payable to PricewaterhouseCoopers LLP for audit and related services for fiscal 2026, consistent with the Committee’s delegated oversight responsibilities. Management frames this as a governance housekeeping item that aligns with the Audit Committee’s charter and the company’s Pre-Approval Policy for audit and permissible non-audit services. The supporting disclosure confirms the Audit Committee’s prior engagement process and lists PwC’s 2024–2025 fees, indicating the Committee’s familiarity with historical spend levels and service categories. Granting this authority is customary and intended to allow the Committee to negotiate and approve fees without requiring a separate shareholder vote for amounts within the ordinary course. From a control perspective, retaining fee-setting at the committee level is consistent with best practices for auditor independence and avoids operational delays that might arise from escalating routine fee decisions to the full Board or shareholders. Risks to shareholders are limited because the Audit Committee remains responsible for evaluating auditor independence and pre-approving non-audit services; the proxy discloses the Committee’s Pre-Approval Policy and its consideration of SEC independence rules. In sum, this is a routine governance proposal to operationalize the Audit Committee’s oversight of external audit spend, with limited strategic implications but appropriate for shareholder approval as presented.

This management resolution asks shareholders to formally receive the Company’s U.K. statutory annual accounts and reports for the 2025 financial year, and to note management’s recommendation not to pay a dividend. Functionally, this is a presentation-and-receipt resolution mandated by U.K. company law—shareholders are afforded the opportunity to review and question the statutory accounts and directors’ reports, including the audited portion of the directors’ annual report on compensation. The company’s disclosure makes clear that the result of this advisory receipt vote will not force board action but will provide shareholders a formal mechanism to express their views on the financial statements and accompanying narrative. For investors, the substantive implications are limited: the vote does not alter accounting, dividend policy, or operational decisions, but it is an important transparency checkpoint where governance and financial reporting can be publicly examined. The Board’s recommendation to vote FOR reflects its view that the accounts fairly present the company’s financial position and performance for 2025; the proxy also explains that the Board will consider shareholder feedback even though the vote does not mandate specific action. In evaluating the company, analysts should note the accompanying statements that no dividend is recommended, which signals capital allocation priorities (likely reinvestment or balance-sheet preservation). The context—presentation of audited statements including compensation disclosures—means the vote is also a venue for shareholders to register concerns about reporting, audit quality, or executive pay, even if it is non-binding. Overall, this is a routine but governance-relevant proposal that confirms statutory compliance, promotes transparency, and provides investors an opportunity to question management on the 2025 accounts.

This proposal requests a non-binding advisory vote on the Company’s U.K. statutory directors’ annual report on compensation, which is included as Annex A to the proxy. The report details the Company’s compensation philosophy, fixed and variable elements, pension and benefit arrangements, and equity award practices for directors and executive officers, and explains how these are intended to support retention and alignment with shareholder interests. Management frames the vote as advisory—consistent with U.K. and U.S. practice—meaning the Board is not legally bound by the result but will consider shareholder sentiment when setting future compensation. The Compensation Committee discloses governance features such as use of an independent consultant, committee composition, and the link between performance metrics and annual bonuses, which are relevant to assessing potential pay-for-performance alignment. While the vote does not directly change pay outcomes, a significant negative vote could trigger shareholder engagement and potential policy changes; conversely, a strong affirmative vote validates current policy and implementation. From an investor due diligence perspective, analysts should review the quantitative disclosures (single total figure of compensation, bonus outcomes, equity grants and vesting) in Annex A to assess whether pay outcomes are aligned with company performance and shareholder returns. The proxy’s narrative emphasizes that no bonuses paid in 2025 and that long-term equity awarded vested in full where granted, which may inform assessment of realized executive pay versus target. Overall, the proposal is governance-focused, offering shareholders an opportunity to influence executive pay practices through an advisory mechanism and to signal approval or concern that the Board and Compensation Committee will consider in future decisions.